Effect of various dressings on the point of entry of an intravenous drip von Kühne-Ponesch, S, Dielacher, P, Dielacher, C, Koller, W, Kundi, el-Madani, N, Hamedinge, R, Hangel, M, Handel, G, Heinrich, G, Ralis, I, Schmidinger, E, Seper, E, Tomaschtik, M, Wechsler-Fördös, A

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial von Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

Volltext

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up von Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., Schmidinger, M., Suarez, C., Teoh, J., de Velasco, G., Young, M., Gillessen, S.

Volltext

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma von Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

Volltext

Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA) von Yan, Kevin, Rane, Pratik, Schmidinger, Manuela, Peer, Avivit, Druyts, Eric, Burgents, Joseph E., Sundaram, Murali

Volltext

Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC) von Rane, Pratik, Walton, Laura, Schmidinger, Manuela, Peer, Avivit, Mt-Isa, Shahrul, Burgents, Joseph E., Sundaram, Murali

Volltext

Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA) von Rane, Pratik, Yan, Kevin, Schmidinger, Manuela, Peer, Avivit, Druyts, Eric, Burgents, Joseph E., Sundaram, Murali

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

First-line immunotherapy-based combinations for metastatic renal cell carcinoma: Systematic review and network meta-analysis von Quhal, F., Mori, K., Mostafaei, H., Laukhtina, E., Pradere, B., Shariat, S.F., Schmidinger, M.

Volltext

Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: A systematic review and network meta-analysis von Quhal, F., Mori, K., Laukhtina, E., Rajwa, P., Mostafaei, H., Pradere, B., Shariat, S.F., Schmidinger, M.

Volltext

Serum neurofilament light chain in behavioral variant frontotemporal dementia von Steinacker, Petra, Anderl-Straub, Sarah, Diehl-Schmid, Janine, Semler, Elisa, Uttner, Ingo, von Arnim, Christine A.F, Barthel, Henryk, Danek, Adrian, Fassbender, Klaus, Fliessbach, Klaus, Foerstl, Hans, Grimmer, Timo, Huppertz, Hans-Jürgen, Jahn, Holger, Kassubek, Jan, Kornhuber, Johannes, Landwehrmeyer, Bernhard, Lauer, Martin, Maler, Juan Manuel, Mayer, Benjamin, Oeckl, Patrick, Prudlo, Johannes, Schneider, Anja, Volk, Alexander E, Wiltfang, Jens, Schroeter, Matthias L, Ludolph, Albert C, Otto, Markus

Volltext

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris... von Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.

Volltext

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis von Yanagisawa, T., Quhal, F., Kawada, T., Laukhtina, E., Rajwa, P., Von Deimling, M., Pradere, B., Mori, K., Kimura, T., Schmidinger, M., Shariat, S.F.

Volltext

A0835 - Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis von Yanagisawa, T., Quhal, F., Kawada, T., Laukhtina, E., Rajwa, P., Von Deimling, M., Pradere, B., Mori, K., Kimura, T., Schmidinger, M., Shariat, S.F.

Volltext

Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial von Grünwald, Viktor, Motzer, Robert J., Haanen, John B. A. G., Schmidinger, Manuela, Staehler, Michael D., Goh, Jeffrey C., Voog, Eric, Climent, Miguel Ángel, George, Saby, Burgents, Joseph E., Xie, Ran, McKenzie, Jodi, Porta, Camillo

Volltext

117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy von Robinson, I., Schmidinger, M., Hochmair, M.J., Ay, L., Absenger, G., Pichler, M., Nguyen, V.A.F., Richtig, E., Rainer, B., Jansen, C., Sladek, B., Knabl, A., Gasche, N., Valipour, A.

Volltext

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study) von Procopio, G., Bamias, A., Schmidinger, M., Hawkins, R., Rodriguez Sanchez, A., Vazquez, S., Srihari, N., Kalofonos, H., Bono, P., Pisal, C., Hirschberg, Y., Dezzani, L., Ahmad, Q., Suarez Rodriguez, C., Jonasch, E.

Volltext

Validation of the German Revised Addenbrooke’s Cognitive Examination for Detecting Mild Cognitive Impairment, Mild Dementia in Alzheimer’s Disease and Frontotemporal Lobar Degenera... von Alexopoulos, P., Ebert, A., Richter-Schmidinger, T., Schöll, E., Natale, B., Aguilar, C.A., Gourzis, P., Weih, M., Perneczky, R., Diehl-Schmid, J., Kneib, T., Förstl, H., Kurz, A., Danek, A., Kornhuber, J.

Volltext